Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 1

Interventions

fludarabine phosphate 2Psychiatric Rehabilitation 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Mycophenolic Acid 2Methylprednisolone 2Lenalidomide 2Cyclosporine 2Antilymphocyte Serum 2tazarotenic acid 1tazarotene 1sintilimab 1romidepsin 1motesanib diphosphate 1mogamulizumab 1carbendazim 1Valproic Acid 1VAP-cyclo protocol 1Ultraviolet Therapy 1Therapeutics 1Ritonavir 1Radiotherapy 1Polymerase Chain Reaction 1Pharmacogenomic Testing 1Peripheral Blood Stem Cell Transplantation 1Methoxsalen 1Methotrexate 1Melphalan 1Levofloxacin 1Leucovorin 1Ketamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, T-Cell, Cutaneous × tazarotene × Clear all
NCT00779896 2008-10-24

Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study

McGill University

Phase 1/2 Unknown
15 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡